Inhibition of Phosphodiesterases Leads to Prevention of the Mitochondrial Permeability Transition Pore Opening and Reperfusion Injury in Cardiac H9c2 Cells

Inhibition of Phosphodiesterases Leads to Prevention of the Mitochondrial Permeability Transition Pore Opening and Reperfusion Injury in Cardiac H9c2 Cells

  • نوع فایل : کتاب
  • زبان : انگلیسی
  • مؤلف : Guillaume Chanoit , Juan Zhou , SungRyul Lee , Rachel McIntosh , Xiangjun Shen , David A. Zvara , Zhelong Xu
  • چاپ و سال / کشور: 2011

Description

(PDEs) with IBMX (1-methyl-3-isobutylxanthine) can modulate the mitochondrial permeability transition pore (mPTP) opening by inactivating glycogen synthase kinase 3â (GSK-3â). Methods H9c2 cells were exposed to 600 ىM H2O2 for 20 min to cause the mPTP opening. Mitochondrial membrane potential (ؤYm) was assessed by imaging cells loaded with tetramethylrhodamine ethyl ester (TMRE). Cell viability was measured with propidium iodide (PI) fluorometry using a fluorescence reader. Ischemia/reperfusion injury was induced by exposing cells to ischemic solution for 90 min followed by 30 min of reperfusion. Results IBMX reduced loss of ؤYm caused by H2O2, indicating that inhibition of PDEs can prevent the mPTP opening. However, IBMX could not inhibit the pore opening in cells transfected with the constitutively active GSK-3â (GSK-3â-S9A) mutant, suggesting a critical role of GSK-3â in the action of IBMX. IBMX also reduced reperfusion injury in a GSK-3â dependent manner. In support, IBMX increased GSK-3â phosphorylation at Ser9, an effect that was reversed by both the PKA inhibitor H89 and the PKG inhibitor KT5823. In support, IBMX activated both PKA and PKG. IBMX failed to prevent the loss of ؤYm in the presence of H89 or PKA siRNA. Similarly, both KT5823 and PKG siRNA reversed the protective effect of IBMX. Conclusion Inhibition of PDEs prevents the mPTP opening by inactivating GSK-3â through PKA and PKG. GSK-3â is a common downstream target of PKA and PKG. Inhibition of PDEs may be a useful approach to prevent reperfusion injury.
Cardiovasc Drugs Ther (2011) 25:299–306 Published online: 4 June 2011
اگر شما نسبت به این اثر یا عنوان محق هستید، لطفا از طریق "بخش تماس با ما" با ما تماس بگیرید و برای اطلاعات بیشتر، صفحه قوانین و مقررات را مطالعه نمایید.

دیدگاه کاربران


لطفا در این قسمت فقط نظر شخصی در مورد این عنوان را وارد نمایید و در صورتیکه مشکلی با دانلود یا استفاده از این فایل دارید در صفحه کاربری تیکت ثبت کنید.

بارگزاری